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OBJECTIVES We tested whether long-term administration of antioxidant vitamins C and E improves
coronary and brachial artery endothelial function in patients with coronary artery disease
(CAD).
BACKGROUND Endothelial function is a sensitive indicator of vascular health. Oxidant stress and oxidized
low-density lipoprotein (LDL) impair endothelial function by reducing nitric oxide bioavail-
ability in the artery wall.
METHODS We randomly assigned 30 subjects with CAD to combined vitamin E (800 IU per day) and
C (1,000 mg per day) or to placebos in a double-blind trial. Coronary artery endothelial
function was measured as the change in coronary artery diameter to acetylcholine infusions (n
 18 patients), and brachial artery endothelial function was assessed by flow-mediated
dilation (n  25 patients) at baseline and six months. Plasma markers of oxidant stress
(oxidized LDL and autoantibodies) were also measured.
RESULTS Plasma alpha-tocopherol (p  0.001) and ascorbic acid (p  0.02) increased with active
therapy. Compared to placebo, there was no improvement in coronary and brachial
endothelial vasomotor function over six months. Although vitamins C and E tended to reduce
F2-isoprostanes (p  0.065), they failed to alter oxidized LDL or autoantibodies to oxidized
LDL.
CONCLUSIONS Long-term oral vitamins C and E do not improve key mechanisms in the biology of
atherosclerosis or endothelial dysfunction, or reduce LDL oxidation in vivo. (J Am Coll
Cardiol 2004;43:629–34) © 2004 by the American College of Cardiology Foundationo
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txcess oxygen-derived free radicals in the vascular wall and
xidation of low-density lipoprotein cholesterol (LDL)
“oxidant stress”) promote cellular processes important in
therosclerosis (1,2). One of the earliest pathogenetic man-
festations of oxidant stress is endothelial dysfunction. It is
sensitive indicator of vascular health that predicts long-
erm cardiovascular outcomes (3) and it is improved rapidly
within hours or weeks) by interventions that take much
onger (usually years) to reduce the risk of cardiovascular
vents (4).
Short-term infusions of high concentrations of the anti-
xidant vitamin C can correct endothelial dysfunction in
atients with a variety of cardiovascular risk factors (4,5).
hese studies provided evidence that oxidant stress impairs
ndothelial function and served as a “proof of principle” that
ntioxidants can improve endothelial function. Yet, in
ecent large-scale clinical trials, oral antioxidants failed to
educe cardiovascular events (6–9). Although the large trials
ave been criticized (10), the long-term effects of oral
ntioxidant vitamins on key biologic features of atheroscle-
osis are poorly defined in humans in vivo.
We conducted a randomized trial of the long-term effect
From the *Brigham and Women’s Hospital and Harvard Medical School, Boston,
assachusetts; †Vanderbilt University, Nashville, Tennessee; ‡University of Califor-
ia at San Diego, La Jolla, California; and the §Children’s Hospital and Harvard
edical School, Boston, Massachusetts. Grant support: NHLBI grants P50
L48743, GM15431, DK48831, and CA77839. Gerald S. Berenson, MD, acted as
uest Editor for this paper.
Manuscript received June 3, 2003; revised manuscript received August 1, 2003,vccepted August 6, 2003.f high-dose oral vitamins C and E on coronary endothelial
unction (primary end point) and the secondary end points
f brachial artery endothelial function and oxidant stress in
atients with stable coronary artery disease (CAD).
ETHODS
tudy design. We conducted a randomized, double-blind,
lacebo-controlled study of the effects of combined vitamins
and E in patients undergoing cardiac catheterization for
valuation of CAD. The subjects had stable exertional chest
ain symptoms and at least a 30% stenosis in one coronary
rtery as evidence of coronary atherosclerosis. Subjects were
xcluded if they had congestive heart failure, a left ventric-
lar ejection fraction 40%, left main coronary artery
tenosis 20%, surgical multivessel coronary disease, acute
oronary syndromes with an elevation of creatinine kinase or
roponin in the previous four weeks, unstable angina as
efined by the Braunwald criteria (11), or if they were taking
ntioxidant supplements. Written informed consent was
btained from all subjects and the study was approved by the
uman Research Committee of the Brigham and Women’s
ospital.
reatment. The active treatment was natural vitamin E
RRR-alpha-tocopherol) (Bronson Labs, American Fork,
tah) 400 IU twice per day and vitamin C (ascorbic acid)
Bronson Labs) 500 mg twice per day. The staff of Inves-
igational Pharmacy encapsulated the active and placebo
itamins and randomly allocated subjects to combined
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ent was stopped 12 h before final assessment of endothe-
ial function to minimize acute effects of these drugs.
oronary endothelium-dependent vasomotor function.
f the 25 patients who completed the study, 4 (16%) had
ild single-vessel disease with a stenosis 30% to 50%, 17
68%) had single-vessel disease with a stenosis 50%, 2
8%) had two-vessel disease, and 2 (8%) had three-vessel
isease (including a 50% stenosis in a side branch of a
tudy vessel).
Coronary endothelium-dependent vasomotor function
as assessed using a protocol established in our laboratory
12,13). The study vessel was selected solely on technical
uitability. Control, acetylcholine (Miochol, OMJ Pharma-
euticals Inc., San German, Puerto Rico) at estimated final
oncentrations of 10-8M, 10-7M, 10-6M, and nitroglycerin
t 25 g/min were administered selectively into the study
oronary artery at 0.8 ml/min for 3 min.
Coronary artery diameters were measured using quanti-
ative coronary angiography (CMS-QCA, MEDIS, Lei-
en, Netherlands), blind to treatment and drug infusions.
asomotor responses were calculated as percent change
rom baseline and the results from three artery segments
ere averaged (12).
rachial artery endothelium-dependent vasomotor func-
ion. Brachial artery endothelial function was assessed
ithin 12 h of the coronary study under the same condi-
ions. The brachial artery was imaged in longitudinal section
ith a Toshiba SSH-140A with a 7.5-MHz linear array
able 1. Baseline Description of the Subjects Randomized to
ombined Antioxidant Vitamins or Placebo
Vitamins C
and E
(n  11)
Placebo
(n  13)
Mean (SD) Mean (SD)
ge (yrs) 59 (12) 62 (10)
DL cholesterol (mg/dl) 110 (25) 99 (18)
DL cholesterol (mg/dl) 38 (7) 42 (12)
riglycerides (mg/dl) 56 (10) 55 (12)
ystolic blood pressure (mm Hg) 146 (27) 151 (19)
iastolic blood pressure (mm Hg) 82 (15) 81 (10)
n (%) n (%)
en 10 (91) 10 (77)
ypertension 6 (55) 8 (62)
mokers 2 (18) 0 (0)
x-smokers 4 (36) 6 (46)
iabetes 4 (36) 3 (23)
amily history of heart disease 7 (63) 6 (50)
Abbreviations and Acronyms
CAD coronary artery disease
IgG  immunoglobulin G
LDL  low-density lipoproteinaDL  high-density lipoprotein; LDL  low-density lipoprotein.ransducer (14). A blood pressure cuff was positioned distal
o the transducer, inflated to 50 mm Hg above systolic
ressure for 5 min, and then released. The artery was
canned 50 to 70 s after cuff deflation (flow-mediated
ilation) and 3 min after sublingual nitroglycerin (0.4 mg)
14). Hyperemia was measured from the Doppler velocity
ime integral. The ultrasound images were digitized at
nd-diastole and brachial artery diameters were measured
lind to treatment assignment using a semi-automated edge
etection program (CVI Analysis, Information Integrity,
tow, Massachusetts). Flow-mediated dilation and nitro-
lycerin dilation were reported as percent change from
aseline diameter.
easurement of blood vitamin levels and oxidant stress.
lood specimens were taken at baseline and six months and
lasma was stored at 70°C. Plasma alpha-tocopherol and
scorbic acid concentrations were measured using high-
erformance liquid chromatography. Plasma free F2-
soprostanes were measured by stable-isotope-dilution mass
pectrometry (15) in a single-batch run. The ratio of
xidized phospholipid epitopes associated with apoB-100
detected by monoclonal antibody EO6) to number of
poB-100 particles (detected by monoclonal antibody
B24) served as an index of oxidized plasma LDL (16).
utoantibodies to oxidized LDL (immunoglobulin G
IgG]) were determined using alkaline phosphatase-labeled
oat anti-human IgG and a chemiluminescent technique
sing Lumi-Phos (Lumigen). Antibody binding was ex-
ressed as relative light units in 100 ms (16).
tatistical analysis. The primary and secondary end points
ere absolute change in endothelial function over six
onths. The change in coronary artery dilation to acetyl-
holine was skewed and reported as medians and interquar-
ile (25% to 75%) range, and differences were tested by the
ank-sum test. The change in brachial artery endothelial
unction was normally distributed and reported as means
and standard errors) and differences assessed by unpaired t
ests. Similarly, the changes in oxidized LDL and its IgG
utoantibody were normally distributed and differences
able 2. Plasma Concentrations of Vitamin E (Alpha-
ocopherol) and Vitamin C (Ascorbic Acid) at Baseline and
ver Six Months
Vitamins C
and E
(n  11)
Placebo
(n  13) p Value
lpha-tocopherol (M)
Baseline 27 (3) 26 (3) 0.8
6 months 57 (9) 23 (3)
Absolute change over
6 months
30 (7) –3 (3) 0.001
scorbic acid (M)
Baseline 36 (7) 41 (6) 0.6
6 months 71 (11) 47 (8)
Absolute change over
6 months
35 (10) 6 (6) 0.02
ata are presented as mean (standard error).ssessed by unpaired t tests. All statistical tests were
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ege Station, Texas).
ower of the study. We used the variability of change in
oronary acetylcholine response observed in the vitamin
roup (standard deviation  13%) to estimate the power of
he study to find important changes in coronary endothelial
unction. In other studies of coronary endothelial function,
herapies that reduce coronary events generally improve the
cetylcholine response by 15% to 25% (12,17,18). With a
tandard deviation of 13%, this study had a 74% power of
nding a 16% difference and a 90% power of finding a 20%
ifference at the 0.05 level.
ESULTS
aseline characteristics. Thirty subjects were enrolled
rom September 1996 to January 1999. Of these, five
iscontinued shortly after enrollment. All 25 subjects re-
urned for the six-month assessment of brachial artery
ndothelial function (one was not recorded because of a
alfunctioning video recorder) and 18 returned for cardiac
atheterization at six months. The baseline characteristics
ere similar for the vitamin and placebo groups (Table 1).
Medications that may influence endothelial function were
istributed similarly between the two groups. At enroll-
ent, a statin was used regularly (daily for 2 weeks) by
hree subjects in the placebo group and five in the vitamin
roup. Statins were started in six subjects, yielding seven
ubjects in each group taking statins over the six months of
he study. Three subjects in the vitamin group and two in
he placebo group used angiotensin-converting enzyme
nhibitors.
lasma vitamin concentrations. The baseline vitamin
oncentrations were similar in both groups of subjects. Over
ix months, the plasma alpha-tocopherol and ascorbate
oncentrations doubled in the subjects assigned to vitamins
nd were significantly greater than the change in the placebo
Table 3. Coronary Artery Endothelium-Depen
Endothelium-Independent (Nitroglycerin) Vas
Vitamins
(n 
Baseline artery diameter (mm)
0 months 2.18 (1.98
6 months 2.09 (1.97
Change over 6 months 0.07 (0.
Maximum acetylcholine (%)*
0 months 7.7 (17
6 months 7.8 (15
Change over 6 months 5.4 (11
Nitroglycerin response (%)*
0 months 13.7 (6.0,
6 months 12.7 (9.0,
Change over 6 months 1.0 (4.
Data are presented as median (25%, 75%). *Percent changeroup (Table 2). coronary endothelium-dependent vasomotor function.
he baseline coronary endothelium-dependent vasomotor
unction was indistinguishable between the two treatment
roups (Table 3). There was no difference in the change in
ndothelium-dependent responses over the six months to
he maximum concentration of acetylcholine tested (Table
) or in the dose response curves to increasing concentra-
ions of acetylcholine (Fig. 1). Endothelium-independent
nitroglycerin) responses at baseline and over six months
ere not different between patients assigned to antioxidant
itamins or placebo (Table 3).
rachial artery endothelium-dependent vasomotor func-
ion. There were no differences between the treatment
roups in hyperemic responses, baseline flow-mediated
ilation or change in flow-mediated dilation over the six
onths of treatment (Table 4, Fig. 2). Similarly, there were
o differences in the endothelium-independent nitroglyc-
rin response at baseline or over the six months of the study
Table 4, Fig. 2).
easures of oxidant stress. The plasma F2-isoprostanes
ecreased more in patients assigned to vitamins at six
onths (p  0.065 overall, p  0.03 for those subjects with
aseline and follow-up coronary endothelial function as-
igure 1. Median endothelium-dependent vasomotor responses to increas-
ng doses of acetylcholine at baseline and at six months follow-up. Open
(Acetylcholine-Mediated Dilation) and
or Responses at Baseline and Six Months
E Placebo
(n  9)
p
Value
) 1.91 (1.58, 2.45) 0.4
) 1.78 (1.61, 2.22)
095) 0.03 (0.18, 0.05) 0.9
8) 12.9 (16.2, 5.9) 0.6
7) 10.5 (16.0, 21.6)
9) 5.2 (1.8, 27.4) 0.8
32.6 (8.9, 47.8) 0.12
27.9 (23.0, 42.8)
) 5.3 (7.5, 11.0) 0.8
red to baseline diameter.dent
omot
C and
9)
, 2.35
, 2.41
16, 0.
.2, 6.
.1, 0.
.6, 8.
27.9)
24.9)
1, 8.9ircles  baseline; solid circles  six months.
s
L
m
D
I
t
w
e
a
d
d
d
d
t
t
O
r
p
b
s
t
c
e
i
s
w
v
t
c
r
v
m
i
i
0
t
c
g
t
a
n
s
t
s
o
(
e
A
m
b
FF(
b
e com
632 Kinlay et al. JACC Vol. 43, No. 4, 2004
Effect of Vitamins E and C on Endothelial Function February 18, 2004:629–34essed) (Table 5). The concentrations of plasma oxidized
DL and its IgG autoantibody did not change over the six
onths (Table 5).
ISCUSSION
n this randomized, double-blind controlled study in pa-
ients with coronary atherosclerosis, six months of treatment
ith high-dose vitamins E and C failed to correct
ndothelium-dependent vasomotor dysfunction in coronary
nd brachial arteries. Although combined vitamins E and C
oubled plasma vitamin concentrations and tended to re-
uce F2-isoprostanes, they did not reduce circulating oxi-
ized LDL or autoantibodies to oxidized LDL. Our study
oes not support a role of combined vitamins E and C for
he treatment of coronary or peripheral endothelial dysfunc-
ion in patients with CAD.
ral antioxidant vitamins and endothelial function. The
ole of increased oxidant stress on endothelial dysfunction in
atients with a variety of coronary risk factors is supported
y the reversal of this dysfunction with intra-arterial delivery of
upraphysiologic doses of the antioxidant vitamin C (4).
igure 2. Brachial artery flow-mediated dilation (FMD) and nitroglycerin
NTG) responses (with standard errors) from baseline to six months. Open
Table 4. Brachial Artery Hyperermia in Respo
Endothelium-Dependent (Flow-Mediated Dila
(Nitroglycerin) Vasomotor Responses at Baseli
Vitamin
(n 
Baseline artery diameter (mm)
0 months 3.81
6 months 4.00
Change over 6 months 0.19
Velocity time integral (%)
0 months 363
6 months 468
Change over 6 months 104
Flow-mediated dilation (%)*
0 months 2.2
6 months 3.1
Change over 6 months 0.9
Nitroglycerin response (%)*
0 months 16.4
6 months 16.2
Change over 6 months 0.9
Data are presented as mean (standard error). *Percent changpars  baseline; solid bars  six months.However, studies that investigated long-term administra-
ion of oral antioxidant vitamins that achieve high physiologic
oncentrations have yielded contradictory effects on periph-
ral artery endothelial function (4,5). Some studies show
mprovement in peripheral endothelial function with oral
upplementation of vitamin E (19,20) or vitamin C (21,22),
hereas others show a lack of benefit for vitamin E (23,24),
itamin C (25,26), or their combination (27). Our study was
he first to examine the effect of oral antioxidant vitamins on
oronary endothelial function.
The inconsistent results of previous studies may be
elated to several factors. To effectively scavenge superoxide
itamin C must be present at concentrations of 1 to 10
mol/l or higher (28). These concentrations were achieved
n short-term parenteral studies, but long-term oral admin-
stration typically raises vitamin C concentrations to only
.1 mmol/l (28), similar to the present study. In the short
erm, vitamin C could also improve endothelial function by
hanges in intracellular redox state by sparing intracellular
lutathione (29), by reduced degradation of tetrahydrop-
erin—a co-factor required for nitric oxide synthesis (30),
nd by reduced protein kinase C activation (31). The
egative results of the present study suggest that the
hort-term effects may not persist with long-term adminis-
ration of vitamin C.
Vitamin E is a lipophilic antioxidant that does not
cavenge superoxide (32). It acts by protecting LDL from
xidation (33), a property that would preserve nitric oxide
2). However, compared to other antioxidants, vitamin E
xerts a weak antioxidant effect (33–35).
ntioxidant vitamins and oxidant stress. Quantitative
easurement of oxidant stress in vivo is difficult but can be
ased on measuring oxidatively modified molecules such as
2-isoprostanes (oxidized arachidonate containing phos-
o Ischemia (Velocity Time Integral),
and Endothelium-Independent
d Six Months
nd E Placebo
(n  13) p Value
) 3.58 (0.20) 0.3
) 3.74 (0.11)
) 0.16 (0.14) 0.9
424 (41) 0.4
392 (60)
32 (61) 0.3
3.9 (1.1) 0.2
4.1 (1.0)
0.2 (0.8) 0.6
21.6 (2.3) 0.11
17.6 (1.8)
2.9 (2.5) 0.6
pared to baseline diameter.nse t
tion)
ne an
s C a
11)
(0.13
(0.19
(0.14
(52)
(77)
(88)
(0.9)
(1.2)
(1.4)
(1.9)
(1.4)
(2.1)holipids [15]) and circulating oxidized LDL (16). Oxi-
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February 18, 2004:629–34 Effect of Vitamins E and C on Endothelial Functionized LDL is highly immunogenic as well as atherogenic,
nd autoantibodies to oxidized LDL are another validated
easure of oxidant stress (16). Although we found that the
ombination of vitamins C and E modestly reduced plasma
2-isoprostanes, it did not lower circulating oxidized LDL
r autoantibodies to oxidized LDL, and this may explain
he lack of benefit on endothelial function.
ower of the study. Because of ethical and technical
onstraints of invasive investigations, studies of coronary
ndothelial function typically investigate fewer subjects than
ther end point studies. Fortunately, testing of coronary
ndothelial function is highly reproducible, and changes can
e demonstrated in relatively small sample sizes. The sample
ize of nine subjects in each group in our coronary study was
ithin the range of other studies that found improvements
n coronary endothelial function with cholesterol-lowering
herapies (9 to 11 subjects per group) (17,36). If antioxidant
itamins had an effect comparable to cholesterol-lowering
herapies, our sample size had a 74% to 90% power of
nding a difference at the 0.05 level. Although we can be
onfident that the present study excluded a substantial and
ence clinically relevant benefit of antioxidants on coronary
ndothelial function, a modest benefit could be excluded
nly by a much larger study.
linical implications. Antioxidant vitamins C and E are
sed widely in clinical practice. However, recent large-scale
linical trials of vitamin E (6,8,9) or vitamins E and C (7) have
ailed to reduce cardiovascular end points either in combination
ith other preventive therapies or alone. Our study provides a
lausible explanation, as the high doses of vitamins used in this
tudy were similar to or exceeded the doses of the large clinical
rials, yet did not improve key features in the biology of
therosclerosis: endothelial function or lipid oxidation. The
ata in this study do not disprove the oxidant stress hypothesis.
hey do suggest that more potent and effective antioxidants are
eeded in this setting.
Table 5. Plasma Concentrations of Markers of
Vitamin
(n
F2-isoprostanes (pg/ml)
Baseline
6 months
Change over 6 months –
Oxidized LDL (EO6/apoB-100)
Baseline 0.2
6 months 0.2
Change over 6 months 0.0
IgG to oxidized LDL (RLU)
Baseline 28
6 months 27
Change over 6 months 1
Data are presented as mean (standard error). *p  0.03 for t
and follow-up.
Ig  immunoglobulin G; LDL  low-density lipoproteicknowledgment
e thank Balz Frei, PhD, for measuring plasma vitamin C
nd E concentrations.
eprint requests and correspondence: Dr. Scott Kinlay, Cardio-
ascular Division, Brigham and Women’s Hospital, 75 Francis
treet, Boston, Massachusetts 02115. E-mail: skinlay@partners.
rg.
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